SPOT-MAS CRC Colorectal Cancer Screening

SPOT-MAS CRC is a blood-based molecular screening test offered by MEDLATEC, designed to analyse biological signals associated with colorectal cancer.

The test uses next-generation sequencing (NGS) and molecular analysis of cancer-associated DNA signals in blood. Unlike multi-cancer screening tests, SPOT-MAS CRC focuses specifically on colorectal cancer.

Key Benefits of SPOT-MAS CRC

• Blood-Based Screening

SPOT-MAS CRC requires a blood sample rather than stool collection or an endoscopic procedure for the initial test.

• Focused Colorectal Cancer Screening

The test focuses on biological signals associated with colorectal cancer, providing a targeted molecular screening option.

• Advanced Molecular Technology

The SPOT-MAS platform uses next-generation sequencing and computational analysis to evaluate cancer-associated molecular signals.

• Convenient Sample Collection

Blood collection generally takes only a few minutes, making the initial appointment convenient for international patients and travellers with limited time.

• Supports Further Medical Investigation

Screening findings may help guide further clinical evaluation when appropriate. Depending on the result and medical history, a doctor may recommend colonoscopy or other diagnostic procedures.

Who May Consider SPOT-MAS CRC?

Patients interested in colorectal cancer screening may discuss this test with a qualified healthcare professional.

Screening recommendations depend on factors including age, family history of colorectal cancer, personal history of colorectal polyps, previous screening results, and other risk factors.

Patients with concerning symptoms, such as rectal bleeding, unexplained weight loss, or persistent changes in bowel habits, should seek medical assessment rather than relying on screening alone.

Testing Process

1. Pre-Test Assessment: Review screening suitability, medical history, and individual risk factors.

2. Blood Sample Collection: A blood sample is collected for laboratory analysis.

3. Molecular Analysis: The sample undergoes molecular testing to assess colorectal cancer-associated signals.

4. Results: Results are generally expected in approximately 15 working days, subject to laboratory confirmation.

5. Follow-Up: Further medical consultation or diagnostic testing may be recommended depending on the results.

Key Data

• Screening Focus: Colorectal Cancer

• Screening Method: Blood-Based Molecular Testing

• Technology: Next-Generation Sequencing (NGS)

• Sample Type: Blood

• Expected Result Time: Approximately 15 working days

Your Healthcare Journey in Vietnam with MediHub

MediHub is a strategic partner of MEDLATEC in supporting international patients travelling to Vietnam for healthcare services.

MediHub provides coordinated assistance throughout the patient's healthcare journey, from initial consultation and travel planning to medical appointments and post-visit follow-up.

Our support services may include:

• Healthcare package consultation and comparison

• Appointment scheduling with MEDLATEC

• Pre-arrival guidance and preparation

• Visa and travel assistance where required

• Airport transfers and local transportation

• Accommodation arrangements

• Medical interpreter coordination

• Assistance during medical appointments

• Medical results and follow-up coordination

• Travel and tourism arrangements during the stay

Plan Your Colorectal Cancer Screening in Vietnam

Considering colorectal cancer screening during your visit to Vietnam?

Contact MediHub to plan your healthcare journey. Our team can help coordinate screening appointments with MEDLATEC, provide preparation guidance, and arrange travel-related support according to your schedule.

Important Medical Information

SPOT-MAS CRC is a screening test, not a definitive diagnostic test. A positive result does not confirm colorectal cancer, and a negative result does not completely exclude it.

Blood-based molecular screening should not replace guideline-recommended colorectal cancer screening methods, such as stool-based tests or colonoscopy, when these are indicated. Patients with concerning symptoms or abnormal screening findings should seek appropriate medical evaluation.